TRISH DAUPHIN: Open Payments
NPI 1740831916 · NEW ORLEANS, LA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,470 in 38 payments from 14 companies in 2025. Trend: 2023 $437 · 2024 $475 · 2025 $1,470
Food & beverage: $1,470
| Company | Payments | Amount |
|---|---|---|
| Gilead Sciences, Inc. | 13 | $334 |
| ViiV Healthcare Company | 7 | $245 |
| Dexcom, Inc. | 1 | $163 |
| Exact Sciences Corporation | 4 | $151 |
| Edwards Lifesciences Corporation | 1 | $125 |
| Lilly USA, LLC | 1 | $123 |
| GENZYME CORPORATION | 1 | $120 |
| Alkermes, Inc. | 2 | $41 |
| Otsuka America Pharmaceutical, Inc. | 2 | $35 |
| Merck Sharp & Dohme LLC | 2 | $34 |
Products named: DEXCOM G7 GSS (161), Yeztugo, CABENUVA, MOUNJARO, FABRAZYME, The Cologuard Plus Collection Kit, APRETUDE, VIVITROL.
Industry payments across LA — which companies pay providers there.
